PANACENT

Serial Number 98488875
688

Registration Progress

Application Filed
Apr 8, 2024
Under Examination
Apr 1, 2025
Approved for Publication
Feb 4, 2025
Published for Opposition
Feb 4, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Oct 01, 2025 65 days

Trademark Image

PANACENT

Basic Information

Serial Number
98488875
Filing Date
April 8, 2024
Published for Opposition
February 4, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Apr 1, 2025
Application
Pending
Classes
042

Rights Holder

Panacent Bio Inc.

03
Address
651 N. Broad St.
Ste. 201
Middletown, DE 19709

Ownership History

Panacent Bio Inc.

Original Applicant
03
Middletown, DE

Panacent Bio Inc.

Owner at Publication
03
Middletown, DE

Legal Representation

Attorney
David S. Kerr

USPTO Deadlines

Next Deadline
65 days remaining
NOA E-Mailed - SOU Required
Due Date
October 01, 2025
Extension Available
Until April 01, 2026

Application History

14 events
Date Code Type Description Documents
Apr 1, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 4, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 4, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 29, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 8, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 7, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 7, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 7, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 22, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 22, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 22, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 21, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 15, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 8, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific research services for both medical and non-medical purposes based on transcriptomics, genomic, and proteomic analyses and providing custom consulting services related thereto; Scientific research services for both medical and non-medical purposes, namely analyses and providing custom consulting services based on single-cell omics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Scientific research services for analysis of clinical trial data providing custom consulting services related thereto; Scientific research services for identification of therapeutic target and pathways based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data, and providing custom consulting services related thereto; Software as a service (SaaS) services featuring software for AI-based identification, collection, curation, and presentation of single-cell data from third party sources; Software as a service (SaaS) services featuring software for AI-based training and generation of translational systems biology models using single-cell data from third party sources, and data from bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based integration and analysis of single-cell data from third party sources and clinical data, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for AI-based analysis of single-cell omics, proteomics, transcriptomics, and genomics; Software as a service (SaaS) services featuring software for identification of therapeutic and cellular pathway target; Software as a service (SaaS) services featuring software for development of novel therapeutic compounds; Software as a service (SaaS) services featuring software for prediction of drug responses and treatment optimization for individual patients based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data and patient-specific data; Software as a service (SaaS) services featuring software for patient stratification based on disease progression or recurrence risk identifying those who may benefit from more aggressive treatment or monitoring based on molecular single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as a service (SaaS) services featuring software for matching patients with clinical trials based on single-cell omics, proteomics, genomics transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data

Classification

International Classes
042